Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
about
Targeting angiogenesis in gynecologic cancersThe estrogen receptor joins other cancer biomarkers as a predictor of outcomeImmunotherapy in endometrial cancer - an evolving therapeutic paradigmContemporary use of bevacizumab in ovarian cancerEndometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasSHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α levelFulvestrant for the treatment of endometrial cancer.Fool's gold, lost treasures, and the randomized clinical trial.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group studyA phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Therapeutic advances in women's cancersA phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group studyChemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.Personalized therapy in endometrial cancer: challenges and opportunities.Molecular staging of gynecological cancer: What is the future?Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229NMetformin: a modulator of bevacizumab activity in cancer? A case reportA phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowIntegrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery.Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers.Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.Molecular blockade of angiogenic factors: A new therapeutic tool for the treatment of abnormal uterine bleedingPersonalized care in uterine cancer.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53Current status of molecular-targeted drugs for endometrial cancer (Review).Recent Advances in Endometrial Cancer.Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.Oncolytic vaccinia virotherapy for endometrial cancer
P2860
Q26824766-D2BA2222-A79D-4F96-8860-E990AAF4D286Q26865554-9CB9BB8A-65D6-496E-AF63-43F2C143BD97Q27020910-A76CDC87-5F3B-4944-85ED-3510F98D872FQ27023510-F1EB8854-26DA-425D-BE1D-65368AB1CCFBQ28074769-CD6B0989-D3A5-4F09-93E7-96416259FAAFQ33740510-F5D4851B-1EA1-465D-8894-CF178AE0EC0FQ34514391-830D9D24-9506-4723-BD21-EFE3B0246324Q34669260-70C2E124-7F49-4C28-A337-EE6FA2B27AB8Q34781699-0D92BEE2-D254-4F1B-8242-BFBC36A30B27Q34951783-BC7AAD2F-3368-4CF1-B414-7BA3F48D4AB2Q35144264-B800E95D-6FE8-48EA-8B97-8345DF88C043Q35180428-B35B5E8E-9DA8-4144-B94D-8DABD5F136D0Q35216723-791CB66E-3130-4330-AEE0-6606A0462865Q35418973-2FC048BD-3B34-45BE-9728-720CB12CCE89Q35748507-0B40DE92-5FF7-48A8-A842-D834B7EF5019Q35769337-8A086CC4-2D59-4118-85C1-91F1E5BF51A4Q35911350-725C0362-8B68-4C44-9772-8C5FE1C8699CQ35940829-B43D5AC9-ABA5-479A-BC2C-D9C616CE05D7Q36191443-F932B22A-41A6-43EF-820C-E9BC77B54EAAQ36214971-3807A1E6-4664-4D1C-9A0A-DD4C95DA136FQ36274386-09CA0DBB-BD45-4013-8255-D7D282825DD9Q36372293-FD3B44E3-4086-47D8-AC87-6FD74D1B1497Q36387267-56B22742-9CAB-4CC7-AC6D-CAD3705B71ADQ36407018-FD43315E-231A-4486-B8B6-CBF935623432Q36598756-6075CD28-5A5B-4248-A17D-367DC763D27FQ36687666-AA85FC61-6BEC-4E8B-99F2-772E6946C1B8Q36731185-495E8BC0-E9A7-49F3-BD63-0FE90E62B969Q36905799-A420AADD-4A91-43A5-AEB5-559F3B34C696Q36944293-ADC4C6CA-2F39-4287-A4DF-19ED70999C2BQ36946683-8B22AD61-C850-4470-967D-495F2B67F939Q36959292-C0454960-924E-486A-A1AD-BF59A45D0BD3Q36977417-F7F3BFD6-AE2C-4E32-B2D0-BB01B0551C57Q36984349-3920B3AE-14B4-449F-831A-2A3E6D735AA1Q37006856-B30CD195-F685-4E97-9A5B-1C9BD74098B4Q37061044-F7C0D77F-423D-4D44-AF2A-88750ECAB119Q37411955-C6BCAC1C-293B-4F90-A8FA-BC7EF29B83EFQ37560813-CBA6FC97-1CBE-4776-B076-BA854E43E850Q37620470-75EAD82A-AD03-4797-B398-2A689BC6BD89Q37625385-2A4553AB-3D8A-4C07-AB34-9145720DE017Q37688850-DCAA4284-1111-412F-A0D8-446D26611558
P2860
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II trial of bevacizumab ...... necologic Oncology Group study
@ast
Phase II trial of bevacizumab ...... necologic Oncology Group study
@en
type
label
Phase II trial of bevacizumab ...... necologic Oncology Group study
@ast
Phase II trial of bevacizumab ...... necologic Oncology Group study
@en
prefLabel
Phase II trial of bevacizumab ...... necologic Oncology Group study
@ast
Phase II trial of bevacizumab ...... necologic Oncology Group study
@en
P2093
P2860
P3181
P356
P1476
Phase II trial of bevacizumab ...... necologic Oncology Group study
@en
P2093
Benjamin Greer
Carol Aghajanian
D Scott McMeekin
Jacob Rotmensch
Kathleen M Darcy
Kimberly K Leslie
Mack N Barnes
Michael W Sill
Parviz Hanjani
Peter G Rose
P2860
P304
P356
10.1200/JCO.2010.32.6397
P407
P577
2011-05-02T00:00:00Z